Report

The Microbiology Testing Market size is estimated at USD 5.65 billion in 2024, and is expected to reach USD 8.78 billion by 2029, growing at a CAGR of 9.22% during the forecast period (2024-2029).

With the COVID-19 outbreak, there was a surge in demand for COVID-19-related diagnostic kits, assay reagents, equipment, and services initially, which had a significant impact on microbiology testing services. For instance, according to an article published by PubMed Central in September 2022, during the pandemic in early 2020, many clinical microbiology laboratories experienced backorders and supply chain issues for many routine tests and associated testing supplies, such as swabs, transport media, and extraction reagents. Laboratories experienced staffing shortages as more trained technologists were needed to meet the demand for continuous SARS-CoV-2 testing and staffing was also limited to reduce exposure risk or for quarantine. So, the COVID-19 pandemic had a significant impact on the market initially, however, currently as the pandemic has subsided and fewer people are getting infected with the virus, fewer diagnostic tests are needed for COVID-19. Moreover, the diagnosis of other diseases has increased and hence, the studied market has started to gain traction and it is expected to have stable growth during the forecast period of the study.

The propelling factors for the growth of the microbiology testing market include technological advancements in microbiology testing, rising incidences of infectious diseases, growing healthcare expenditure, and rising private-public funding for research on infectious diseases.

Infectious diseases, such as HIV, human papillomavirus (HPV), and hepatitis B and C, are some forms of STDs that are severe and fatal, and thus the increasing incidences of such diseases are increasing the demand for the microbiology testing market. For instance, according to an article published by the virology journal in September 2022, human papillomavirus (HPV) is considered one of the most commonly encountered sexually transmitted infections, which is responsible for causing cervical cancer and other cancers including vaginal, vulvar, anal, penile, and oropharyngeal cancer. More than 200 HPV genotypes have been identified, and they can be classified into high-risk (HR) and low-risk HPV (LR) genotypes based on their carcinogenicity. Furthermore, increasing healthcare expenditure and the presence of better medical infrastructures, such as hospitals and clinical labs, are some other drivers augmenting the growth of the microbiology testing market.

Additionally, as per the data published by the WHO in August 2022, more than 1 million sexually transmitted infections are acquired globally every day and most of them are asymptomatic. It also reported that every year there are an estimated 374 million new infections with 1 out of 4 sexually transmitted infections such as gonorrhea, chlamydia, trichomoniasis, and syphilis.

The market players are adopting various strategies such as acquisitions, collaborations, partnerships, and expansions of services to increase market share. For instance, in June 2022, STEMart launched microbiology and sterility testing for sterile and non-pyrogenic medical devices. Hence, increasing service launches by key market players are expected to enhance the market growth during the forecast period of the study.

Thus, the factors such as increasing incidence of infectious diseases and various strategies adopted by market players such as acquisitions, collaborations, partnerships, and expansions of services are expected to drive the growth of the microbiology testing market. However, factors such as laboratory reimbursement issues and the high cost of microbiology instruments may impede market growth in the near future.

Microbiology Testing Market Trends

Diagnostics Segment is Expected to Hold Significant Share Over the Forecast Period

The diagnostics segment is expected to hold a significant share of the microbiology testing market. Some of the key factors driving the growth of this segment are the increasing prevalence of infectious diseases, improving healthcare expenditure and rising emphasis on effective and early disease diagnosis across major markets, and the introduction of advanced, accurate, and rapid methods for faster clinical diagnosis.

For instance, according to an article published by NCBI in October 2022, antimicrobial susceptibility testing is very useful in patient management as it helps in the identification of the specific diagnosis, and additionally, it targets the particular etiologic agent causing the disease. As no two patients can be managed similarly, especially if they have the same disease manifestation but the causative organism can have different resistance patterns, in such cases antimicrobial susceptibility testing helps in determining whether a particular drug is going to work for that causative agent or not. Furthermore, according to the data by UNAIDS in 2022, an estimated 38.4 million people globally were living with HIV in 2021 and 1.5 million people became newly infected with HIV in 2021. Hence, the increasing adoption of microbiological testing methods for various diagnostic purposes and the increasing prevalence of various diseases is expected to enhance the segment growth.

Furthermore, continuous product launches by major players in the market are positively affecting the growth of the segment. For instance, in July 2021, Bruker launched new microbiology products and workflows for microbial identification and infection control. It includes products such as MBT Lipid Xtract kit which expands the research capabilities even beyond rapid microbial identification.

Thus, factors such as increasing prevalence of infectious diseases such as HIV and continuous product launches for diagnosis of the disease by market players are likely to drive the segment growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

Some of the factors that are driving the market growth in the North American region include better healthcare infrastructure, the rising burden of infectious diseases and outbreaks of epidemics, technological advancements in microbiology testing, and the presence of key market players in the country.

Well-established healthcare infrastructure and increasing healthcare spending are two of the key factors for the growth of the market in the region. For instance, according to the data by NIH in May 2022, the funding for antimicrobial resistance research is estimated to increase from USD 656 million in 2021 to USD 665 million in 2022. Such increasing investment in research by the government is propelling the growth of the market in the region.

Furthermore, the rising prevalence of infectious diseases in the region is also boosting the market growth. For instance, according to the data published by CDC in June 2022, it is estimated that in the most recent five years, approximately 14,000 to 25,000 cases of invasive group A strep disease occurred each year in the United States. Furthermore, as per the report published by the Centers for Disease Control and Prevention in April 2022, around 677,769 cases of gonorrhea were reported in 2020. Gonorrhea also emerged as the second most common noticeable sexually transmitted infection in the United States. Hence, the increasing prevalence of infectious diseases is expected to enhance the market growth.

The market players are adopting various strategies such as product launches, developments, acquisitions, collaborations, partnerships, and expansions to increase market share. For instance, in March 2022 Bureau Veritas launched a microbiology laboratory that will offer rapid pathogen testing for E.coli, Listeria, Salmonellas, yeast, and Mold in Canada. Such establishment of the facilities is expected to increase the accessibility of testing and thus expected to propel the growth of the market in the region.

Thus, the rising prevalence of infectious diseases and the presence of better healthcare infrastructure are the major factors driving the growth of the market, in the North America region.

Microbiology Testing Industry Overview

The microbiology testing market is moderately competitive in nature. The companies have witnessed new product launches, mergers and acquisitions, partnerships, joint ventures, and strategies adopted by the major players to gain a competitive advantage. The companies are also introducing advanced microbiological automated systems that have high throughput and are less time-consuming. Some of the key players include Bio-Rad Laboratories Inc., Abbott Laboratories, Becton Dickinson and Company, F. Hoffmann-La Roche Ltd., Bruker Corporation, Hologic Corporation, Danaher Corporation (Cepheid Inc.), Biomerieux SA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Merck KGaA, Shimadzu Corporation, and NEOGEN Corporation, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support